Aqemia
Founded Year
2019Stage
Grant | AliveTotal Raised
$108.31MLast Raised
$7.4M | 6 mos agoRevenue
$0000Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-21 points in the past 30 days
About Aqemia
Aqemia focuses on transforming the drug discovery process. The company offers technology that combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a rapidly growing pipeline of new drug candidates. It primarily sells to the pharmaceutical industry. It was founded in 2019 and is based in Paris, France.
Loading...
ESPs containing Aqemia
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The quantum computing for drug discovery market leverages quantum algorithms and computing infrastructure to accelerate pharmaceutical research and development. These providers offer quantum-enhanced solutions for molecular simulation, drug candidate identification, binding prediction, and protein folding analysis that surpass classical computing capabilities. Companies combine quantum computing w…
Aqemia named as Challenger among 15 other companies, including IBM, Microsoft, and SandboxAQ.
Aqemia's Products & Differentiators
Drugs
At AQEMIA, we invent small molecule pre-clinical candidates for therapeutic targets that are currently unexplored or remain undruggable
Loading...
Research containing Aqemia
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Aqemia in 8 CB Insights research briefs, most recently on Aug 22, 2025.
Aug 22, 2025 report
Book of Scouting Reports: Generative AI in Healthcare & Life Sciences
May 23, 2025
The AI in drug R&D market map
Jan 11, 2024
The generative AI in healthcare market map
Jan 8, 2024
4 applications of generative AI in drug R&D
May 9, 2023
7 applications of generative AI in healthcareMay 9, 2023
7 applications of generative AI in healthcareExpert Collections containing Aqemia
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aqemia is included in 7 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
12,998 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
11,439 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
AI 100 (All Winners 2018-2025)
100 items
Generative AI 50
50 items
CB Insights' list of the 50 most promising private generative AI companies across the globe.
Generative AI
2,826 items
Companies working on generative AI applications and infrastructure.
Latest Aqemia News
Aug 22, 2025
SUMMARY AQEMIA AQEMIA , a French startup focused on using AI and quantum-inspired physics for drug discovery, has raised €94.9 million in total funding. Gigs Gigs , the operating system for mobile services, announced that it has raised a $73M Series B led by Ribbit Capital. All existing investors, including Google's Gradient, YC and Speedinvest participated in the round ANYbotics ANYbotics , a global leader in AI-driven robotic inspection solutions, has raised an additional $60 million, bringing its total funding to over $130 million. Dealfront Germany-based Dealfront has raised €30 million in funding from AshGrove Capital. Dealfront is a B2B sales intelligence platform that helps sales and marketing teams find, target, and secure quality leads using GDPR-compliant data, insights, and tools. bsport Barcelona-based bspor t, a platform for wellness studios, has raised €30 million in Series B funding, led by Base10 Partners and Octopus Ventures. Other investors include Stanford University, Seventure Partners, and Seed4Soft. Aisti Aisti has successfully raised €29 million in a Series A funding round to boost the production of its innovative acoustic tiles, made from renewable wood fibers. Mynt Mynt , a company that offers corporate credit cards and spend management software, has raised €22M in funding, bringing its total funding to over €50M. The round was led by Vor Capital, with support from existing investors like CNI and Incore. Next Sense Next Sense , a leading provider of Smart BuildingPlatform SaaS solutions, has announced the successful close of an €11.5 million Series A investment round. Waterfall Network Switzerland based smart contract platform Waterfall Network has raised $11.6 million in a funding round led by Bolt's Capital, Alpha Token Capital, and Enflux. Faqs - Funding Roundup in This Week Name the Top European Startups Funding Roundup in This Week( December 9 – December 13, 2024)? Nscale, AQEMIA, Gigs, ANYbotics, Dealfront, bsport, Aisti, Mynt, Next Sense, Waterfall Network, are the top 10 European Startups Funding Roundup in This Week.
Aqemia Frequently Asked Questions (FAQ)
When was Aqemia founded?
Aqemia was founded in 2019.
Where is Aqemia's headquarters?
Aqemia's headquarters is located at 1 Boulevard Pasteur, Paris.
What is Aqemia's latest funding round?
Aqemia's latest funding round is Grant.
How much did Aqemia raise?
Aqemia raised a total of $108.31M.
Who are the investors of Aqemia?
Investors of Aqemia include France 2030, Elaia Partners, Wendel, Eurazeo, Bpifrance and 8 more.
Who are Aqemia's competitors?
Competitors of Aqemia include Variational AI, Insilico Medicine, Cradle, Biomatter, Valence Labs and 7 more.
What products does Aqemia offer?
Aqemia's products include Drugs.
Loading...
Compare Aqemia to Competitors
Insilico Medicine focuses on artificial intelligence in drug discovery and development. The company provides artificial intelligence platforms for multi-omics target discovery, deep biology analysis, automated drug design, and predicting outcomes in clinical trials. The technologies are intended to assist in the process of discovering and developing new medications for various diseases. It was founded in 2014 and is based in New Territories, Hong Kong.
Cradle focuses on protein engineering in the biotechnology sector, using machine learning to optimize protein sequences. It provides tools for designing improved variants of target proteins, integrating laboratory data, and predicting performance to support research and development. Its solutions are relevant for biotech teams working on various applications, including therapeutics, enzymes, vaccines, peptides, and antibodies. It was founded in 2021 and is based in Amsterdam, Netherlands.
InstaDeep focuses on delivering artificial intelligence (AI)-powered decision-making systems for various enterprise sectors. The company offers solutions that leverage computing, deep learning, and reinforcement learning to address challenges in industries such as biology, logistics, electronic design, and energy. Its products and services are designed to help the capabilities of businesses by providing advanced AI tools and research insights. InstaDeep was formerly known as Digital Ink Group. It was founded in 2014 and is based in London, United Kingdom.
YDS Pharmatech is a company focused on drug discovery in the pharmaceutical industry. The company offers a platform for the design of new drug candidates, utilizing structure-based de novo drug design and evolutionary AI to accelerate the drug discovery process. YDS Pharmatech primarily serves the pharmaceutical industry. It was founded in 2020 and is based in Albany, New York.
Isomorphic Laboratories serves as a digital biology company that operates in the pharmaceutical and artificial intelligence sectors. The company's main service is to use artificial intelligence, specifically machine learning, to transform and expedite the drug discovery process. The company primarily serves the pharmaceutical industry. It was founded in 2021 and is based in London, United Kingdom.
Variational AI is a company focused on drug discovery utilizing generative AI within the biopharmaceutical sector. The company offers Enki, a platform that generates novel drug-like small molecules based on user-defined therapeutic product profiles (TPP) without requiring prior data. Variational AI primarily serves the biopharmaceutical industry, collaborating with partners to develop new therapeutics. It was founded in 2019 and is based in Vancouver, Canada.
Loading...